EGFR and neoplasm: As an equivalent alternative to gefitinib, we utilized the first‐generation EGFR‐TKI, icotinib, which has been clinically proven to be equivalent to gefitinib.1, 20 HCC827/IR cells were injected into nude mice and treated when the xenograft volume reached approximately 250 mm3 with icotinib or icotinib combined with E3330 or vehicle alone for 12 days, as the nude mice cannot tolerate tumor load for a longer time.